Hear Why Industry Leaders Choose World ADC
"What stands out the most is the opportunity to contextualize, at a global level, the status and trends of the ADC landscape. Everything is very well organized, and the presentations are insightful”
AstraZeneca
“Best ADC event in Europe”
Pierre Fabre
“An excellent opportunity to listen to the subject matter experts and gaining knowledge”
Arcadis
“Well organized, catered, with rich access to industry expertise through the various conference streams”
BioDlink
“Very nice and comprehensive overview of the ADC field!”
Crossfire Oncology
“Great presentations, and a chance to have offline discussions”
Daiichi Sankyo
“The APP was very useful to follow-up the diverse and wide program”
Debiopharm
“High scientific level in all the presentations and easy to connect in the break out sessions. It has the right size and the app made really easy to navigate the conference”
Worldwide Clinical Trials
“I appreciate the high scientific quality and the strong focus on real-world challenges in ADC development. The integration of academic, industry, and investor perspectives make the experience particularly valuable”
Exiris
“I really enjoy the variety of talks within the pipeline of ADCs and the panel discussions”
GSK
“Excellent speakers and various networking opportunities to connect with others”
H Linkers
“Knowledgeable attendees provided a great cross section of current ADC research and development”
Iksuda Therapeutics
“Attending for the first time, I felt I received a very through and realistic view on the ADC field”
Orion Pharma
“The high scientific quality of presentations and of the discussions and the strong focus on innovation within the ADC field”
OncoBone Therapeutics
“Clear overview on new developments in ADC technology”
Nona Biosciences
“Comprehensive information on ADC research and development”
Merck & Co
“The opportunity to network with some of the heaviest hitters in the industry and meet with prospective Clients in London is not to be missed”
Mabplex
“The ADC focus of the conference allows for a focused discussion of key topics and advances in the field and brings subject matter experts together in a smaller conference that some of the larger conferences we would normally attend”
Kivu BioScience
“A bright, spacious environment with sharp, targeted presentations, insightful KOLs addressing key market issues, and top‑tier scientific conferences”
Jubilant Biosys
“Excellent talks with very exciting topics including preclinical and clinical data”
Innate Pharma
“Attending World ADC is valuable because it provides an opportunity not only to share our work, but also to learn from the broader ADC community. While ADCs have already demonstrated transformative potential, significant opportunities remain to improve efficacy, safety, delivery, and patient selection. These discussions often generate new ideas, perspectives, and collaborations that help advance the science and ultimately benefit patients”
Kevin Hamblett, Senior Director, ADC Pharmacology, Pfizer
“It is a unique and valuable opportunity to present to such a broadly cross-disciplinary audience with a unified focus and expertise in ADCs”
Sam Murphy, Chief Executive Officer, Salubris Biotherapeutics
“The most comprehensive meeting on the ADC modality. Best place to meet innovators in the field”
Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics
“The ADC field is moving very quickly with many different aspects so it is good to share data where available and experiences as a community to more rapidly advance the field”
Harold Keer, Chief Medical Officer, Taiho Oncology
“I have been attending World ADC for many years, but every year, I learn something new that changes how we approach our work. Whether it's a key piece of data from a presentation or an insightful comment by a colleague, it's always worth the trip”
Greg Thurber, Professor in Chemical Engineering, University of Michigan
“The meeting offered a valuable exchange with experts across different fields, with the investor perspective standing out as particularly enlightening. It is a strong opportunity to build a more rounded understanding of ADCs — appreciating not only the scientific and clinical dimensions, but also how the field is viewed by investors and other key stakeholders”
Evelyn Fahrenkrug, Global Commercial Head Oncology Pipeline, Boehringer Ingelheim
“Since that first meeting, Hanson Wade has built the world's leading series of ADC and related modality conferences, becoming a key forum for scientific exchange and strategic collaboration. These meetings, together with their associated databases and industry intelligence resources, have helped the community understand the drivers behind the success of the 21 ADCs approved by the FDA, EMA and/or NMPA, while also providing valuable insights into clinical failures and the emerging opportunities offered by next-generation Extended Drug Conjugates (XDCs)”
Alain Beck, Senior Director, Biologics CMC Developability, Pierre Fabre
“The most important conference for networking in the ADC field. Connecting with long-established scientists in the field as well as making new connections with newcomers to the field who bring new ideas for improving the therapeutic index of ADCs”
John Lambert, Consultant & Honorary Professor, Queen's University Belfast
“It is a nice opportunity to share the data and thoughts with the field and build the network”
Min Hu, Senior Vice President, Oncology Discovery, Innovent Biologics
“World ADC London brings together the leaders and innovators shaping the future of antibody–drug conjugates. For me, the value lies in the quality of the dialogue, exchanging perspectives on where the field is heading, identifying opportunities for collaboration and ensuring that innovation continues to translate into meaningful outcomes for patients”
Dragan Grabulovski, Chief Executive Officer, Araris Biotech
“World ADC London is a valuable opportunity to connect with leaders across the ADC community, exchange perspectives on where the field is heading, and learn from the science and innovation shaping the next generation of ADCs”
Jeremy Sauer, Vice President, Head of Strategy, Callio Therapeutics
"As CMC RA representative it is important to create a forum of exchange of experiences and ideas to foster a strong but efficient regulatory legislation for the field"
Eugenio Cardenal Vigil, Associate Director Regulatory Affairs CMC, Johnson & Johnson
“Extensive cross functional and scientific experience in developing drugs from discovery to drug launch. Passionate about connecting investigators with different expertise and delivering clinically meaningful approaches”
Elisabetta Leo, Senior Director, Early Development Asset Lead, Ipsen Pharma
“WADC is an excellent opportunity to interact with colleagues across the industry to share learnings which will propel ADC development into the future.”
Michael Conner, Senior Principal Scientist – Oncology Research Unit, GSK
"With more than 700 attendees and representatives from over 240 organisations across the ADC ecosystem, the World ADC London Summit is an unparalleled platform for collaboration and knowledge exchange.
I am honoured to join this world-class speaker faculty and showcase how Ona Therapeutics is helping drive innovation in next-generation ADCs through a differentiated, patient-led approach to overcoming treatment resistance."
Valerie Vanhooren, Chief Executive Officer, Ona Therapeutics
“Selective tumor targeting has always been a challenge in oncology with differential expression typically used to define targets. By understanding the spatial relationships within local protein neighborhoods, a new dimension in tumor targeting can be added to this critical decision point in drug discovery. Tumor Associated Proximity Antigens (TAPAs) have proven to be excellent pairings for bispecific ADCs. By identifying proteins that naturally associate, more selective targeting with the potential to access shared biology between targets can be applied to create novel ADC targeting strategies.”
Scott Lesley, President & Chief Scientific Officer, InduPro
“I value the industry focus, the sharing of cutting edge insights & capabilities and the candid discussions regarding the current and future state of ADC drug discovery.”
Matt Gray, Scientific Leader – Discovery Chemistry, GSK
"The meeting brings together the broad range of scientific, commercial and investment expertise that is essential to develop clinically meaningful ADCs. Engagement at all levels reenforces and reignites these critical alliances; driving the passion and dedication needed to continue innovating for our patients."
Dave Simpson, Chief Executive Officer, Iksuda Therapeutics
“Exchange ideas for cancer treatment is one of the most important part of cancer research scientists. This meeting provides one of the best platform in ADC field for people like me to learn from others, to speed up our research for the benefit of the urgently needed patients.”
Jiaqiang Cai, Co-Founder, Chief Scientific Officer & Co-Chief Executive Officer, Medilink Therapeutics
“A great opportunity to contribute and knowledge share at the premier conference in the ADCs”
Simon Burr, Vice President, Novo Holdings
"I value the opportunity to see where the industry is heading, hear about interesting science, and discover new approaches and ideas. I also really value the discussions and networking, where we can exchange perspectives, ask questions, and come away with new insights and inspiration."
Diana Hudecz, Senior Scientist, SOTIO Biotech
“The ADC meeting brings together people from every stage of development, from target identification and linker–payload design to manufacturing, regulatory strategy, and clinical development. I especially value the networking opportunities and informal conversations throughout the event, where perspectives from across the field come together.”
Hanspeter Gerber, Chief Scientific Officer, Sutro Bio
“The role of Potency for CMC Biologics is still often misunderstood, and I appreciate how meetings like ADC London Summit offer opportunities for analytical experts to learn from each other and streamline future product development.”
Colleen Santoro, Principal Scientist, Merck
"This is a leading conference in the ADC field, so an excellent chance to see an overview of recent progress. Most significantly from my perspective, is the chance for academia and industry to interact, which is essential in this area – as ADC construction and applications requires innovation and multidisciplinary approaches."
Jamie Baker, Professor of Chemistry, University College London
“As an oncologist with direct involvement in the preclinical, early and late phase development of ADCs, I see the critical importance of bringing scientists, sponsors and clinicians together at this important ADC conference”
Michael Flynn, Medical Oncology Consultant, University College London Hospital
“Stay updated on latest technological advances in ADC and connected with industry and academic thought leaders”
James Wang, Vice President Business Development, Adcendo
"World ADC brings together leading minds across the ADC ecosystem, making it an important platform to exchange ideas, challenge conventional thinking and advance the next generation of ADC therapeutics. We look forward to sharing Axcynsis’ perspective and learning from peers across the industry"
Bin Zou, Chief Executive Officer, Axcynsis
“World ADC is a great bridge between the Biotech innovation engine and Pharma clinical development experience, where sharing of what works and what is needed seeds new innovation in a fast moving field”
Jon Travers, Director of Business Development & Licensing, Merck & Co
“The session aims to start important discussions about the future of bioanalysis for new modalities, shaping the direction of the field and will explore whether current bioanalytical strategies are necessary for new modalities where cytotoxicity is not a primary concern. This could lead to more efficient, streamlined, and cost-effective development processes”
Sasha Fraser, Senior Scientist – Bioanalytical Strategy, Regeneron
"Taking part offers a valuable opportunity to exchange perspectives with experts across the ADC field and discuss how fit-for-purpose in vitro, in vivo, and emerging model systems can improve the translation of efficacy and safety. I particularly value the opportunity to share practical learnings, hear different approaches, and contribute to advancing more predictive, mechanistically informed models that support better decision-making in ADC development"
Daria Galas-Filipowicz, Clinical Pharmacology & Safety Sciences Oncology Safety Postdoctoral Fellow, AstraZeneca
“World ADC London provides a valuable opportunity to exchange scientific insights with experts across the global ADC community. I look forward to sharing our experience and learning from emerging analytical approaches to address the increasing complexity of ADC development”
Etsushi Yoshikawa, Scientist, Astellas Pharma
“With many ADCs showing preclinical and clinal activity, early evidence of efficacy is not enough. The next chapter for ADCs will be defined by how thoughtfully we connect innovation with clinical development—choosing the right targets and payloads, identifying the patients most likely to benefit, and optimizing doses and combinations”
Grzegorz Nowakowski, Senior VP, Head of Global Early Development Organization, Daiichi Sankyo
"I have always found World ADC events highly valuable because they bring together many of the leading experts, innovators and companies shaping the ADC field, and have helped create a genuine community around the modality. ADCs are inherently collaborative by nature, integrating multiple technologies, disciplines and areas of intellectual property. Progress therefore depends on timely information exchange, open dialogue and strong connections across different areas of expertise. World ADC provides an excellent forum for that interaction, supporting the collaboration and partnering that are essential to advancing the field. "
George Badescu, Chief Business Officer, Heidelberg Pharma
“As Servier's strategic interest in expanding its targeted oncology pipeline through next-generation ADC grows, this meeting provides an opportunity to scout cutting-edge platforms and source early-stage oncology assets. ”
Irene Blat, Head of External Innovation, Servier
“World ADC brings together the full breadth of expertise required to develop ADCs, from targets, payloads and bioanalytics through CMC, manufacturing, regulatory strategy and partnering. For CMC leaders in particular, it provides an important forum to stay current with evolving development and regulatory expectations, exchange practical experience, and connect the specialist disciplines needed to translate complex ADC technologies successfully into the clinic”
Christian Lutz, Senior Director CMC, Heidelberg Pharma
"World ADC represents an excellent opportunity to exchange scientific knowledge and engage with researchers and industry experts working on next-generation targeted cancer therapeutics. I particularly value the opportunity to bring a small-molecule perspective to the broader field of drug conjugates, share recent advances in targeted drug delivery, and explore how novel payloads may expand the therapeutic potential of drug conjugates in oncology"
Matilde Bocci, Research Scientist, Philochem
Explore the Agenda
- 700+ ADC Industry Leaders Across Biopharma, Academia & Solution Providers
- 110+ Global ADC Experts & Industry Visionaries
- 5 Tracks of End-to-End ADC Innovation
- Brand-New Partnering Platform & Enhanced Networking Experiences
- Europe's Largest Gathering of the ADC Community
